Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Technology
INVESTOR'S BUSINESS DAILY and JULIE MAK

Exelixis Stock Shows Rising Relative Price Performance; Still Shy Of Key Benchmark

In a welcome move, Exelixis stock saw its Relative Strength Rating improve from 69 to 73 on Monday.

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD's unique rating measures price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.

Decades of market research reveals that the best stocks tend to have an 80 or higher RS Rating in the early stages of their moves. See if Exelixis stock can continue to show renewed price strength and hit that benchmark.

Looking For Winning Stocks? Try This Simple Routine

Is Exelixis Stock A Buy?

While it's not currently an ideal time to Exelixis shares, see if the stock is able to establish and enter a buy zone in heavy trade. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.

 

The biotech company reported 0% EPS growth last quarter, while sales growth came in at -6%.

Exelixis stock earns the No. 48 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm and Vertex Pharmaceuticals are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.